Nanomedicine Therapeutics Startup
August 24, 2026
Through our global network of testing experts and analytical equipment including chromatography (HPLC, GC, GC/MS) and atomic absorption spectroscopy (AAS, GFA, FIAS), Our goal is to provide test services as efficiently as possible to maximize our customers' profits. For more information about our services, contact one of our experts today.
Note: this service is for Research Use Only and Not intended for clinical use.
In clinical applications, some biomedical nanomaterials are often introduced into blood tissue by intravenous injection, penetration, dissolution, and diffusion. Blood is a highly complex tissue, mainly composed of red blood cells, white blood cells, platelets and plasma. Among them, plasma is a complex body fluid, which contains more than 3700 different proteins. These nanomaterials will inevitably have some kind of connection or interaction with abundant plasma proteins (or other blood components) no matter which way. The interaction between nanomaterials and plasma proteins may change the structure, conformation and polarity of plasma proteins, and eventually lead to the exposure of new antigenic determinants and change the function of plasma proteins, resulting in the toxicity of nanomaterials in vitro or in vivo. A clear understanding of this issue will help guide the safety design of nanomaterials.

Nanomaterials in a blood associate with a range of proteins, organized into the protein "corona"
| Function | Analytical Methods |
|---|---|
| Observation of the nanomaterials/protein complexes formation | Transmission electron microscopy (TEM) Atomic force microscopy (AFM) |
| Binding affinity and ratio of nanomaterials interaction with protein | UV-vis spectroscopy (UV) Fluorescence spectroscopy Dynamic light scattering (DLS) |
| Structure changes of nanomaterials-bound protein | Circular dichroism spectroscopy (CD) Fourier transform infrared spectroscopy (FT-IR) Raman spectroscopy Small-angle X-ray scattering (SAXS) Electron paramagnetic resonance (EPR) |
| Isolation and separation of nanomaterials-bond proteins | Gel electrophoresis (GE) Capillary electrophoresis (CE) Gel permeation chromatography (GPC) High performance liquid chromatography (HPLC) |
| Identification of nanomaterials-bound proteins | Mass spectrometry (MS) N-terminal microsequencing |
| Kinetics of nanomaterials-proteins binding | Quartz crystal microbalance (QCM) Surface plasmon resonance (SPR) |
| Thermodynamics of nanomaterials-protein binding | Differential scanning calorimetry (DSC) Isothermal titration calorimetry (ITC) |
Interaction test between polycation and plasma protein
Polycations are a kind of polymer materials with positive charge on the surface, such as polyethyleneimine, chitosan, polyamide-amine, etc., which can be used as gene delivery carriers. With the deepening of the research, it is found that these polycationic carriers generally have obvious cytotoxicity, which limits the production and commercialization of polycationic gene carriers. In addition, when polycation is used in vivo, it may also cause other toxicity, such as immunotoxicity and hemolytic toxicity.
Interaction test of polymer micelles with plasma proteins
Polymer micelles are supramolecular nanoparticles with core-shell structure formed by self-assembly of amphiphilic polymers in aqueous solution. In the targeted delivery of hydrophobic drugs, smart polymer micelles are an ideal drug carrier. The hydrophobic core of polymer micelles can provide loading space for hydrophobic drug molecules, increase the solubility of hydrophobic drugs, and prolong the circulation time of drugs in the body; on the other hand, the functional responsiveness of micelles can be used to achieve targeted drug release in a specific time and space. However, as a polymer micelle used in vivo, it is also inevitable to contact with plasma proteins and interact with each other.
Interaction test of drug (gene) / carrier composite nanoparticles and plasma proteins
In clinical application, when patients take medicine, it is not only the drug that enters the body, but also its carrier, that is, the drug (gene) / carrier composite nanoparticles enter the body. When these composite nanoparticles contact with plasma proteins, there may be three kinds of interactions between them: (1) the interaction between drugs and plasma proteins; (2) the interaction between carriers and plasma proteins; (3) the interaction between drug (gene) / carrier composite nanoparticles and plasma proteins.
Interaction test of other polymer nanomaterials and plasma proteins
There are many kinds of polymer nanomaterials, including not only polycations, micelles and composite nanoparticles, but also anionic polymer polyelectrolytes such as polyacrylic acid, neutral polymers such as polyvinyl alcohol and PEG, and polymer vesicles of various shapes. Although plasma proteins are generally negatively charged, there are still positively charged plasma proteins; at the same time, uneven charge distribution can also make plasma proteins locally positively charged. Therefore, anionic polymers may produce electrostatic interactions, hydrogen bonding interactions, and hydrophilic-hydrophobic interactions with plasma proteins.

As a professional third-party organization, Alfa Chemistry's professional capabilities are rooted in a long and successful history. With many years of testing experience, we can provide independent, fast-response, and cost-effective nanomaterial analysis services to help you shorten the time to market products, reduce risks, and increase the market value of products.
How do you manage complex colloidal behaviors, such as aggregation, precipitation, or optical interference, when exposing blood matrices to unique nano-formulations?
Our lab employs specialized pre-screening dispersion stability checks, baseline optical absorbance corrections, and control filtering protocols to prevent nanoparticle interference with microplate assays and spectrophotometric readings.
What measures are taken to maintain strict biological lot consistency and donor-to-donor variability control during multi-batch hemocompatibility evaluations?
We utilize qualified pooled human plasma and fresh donor blood matrices that adhere to strict institutional review board criteria, alongside standardized positive and negative controls to ensure absolute reproducibility across longitudinal validation phases.
What is the standard turnaround time for a complete hemocompatibility profiling package, and how do you handle expedited submissions for regulatory filing deadlines?
Comprehensive evaluations typically require 10 to 14 business days due to multi-stage incubation and kinetic monitoring. For tight IND or ISO 10993 submission windows, prioritized queuing can be arranged upon project intake.
How are raw data sets and dynamic kinetic measurements structured for direct inclusion in our toxicological dossiers and regulatory submissions?
All data packages include complete raw absorbance spectra, time-course hemolysis curves, and statistical variance reports formatted to align with standard international biocompatibility guidelines.
What level of scientific consultation is provided if our candidate nanomaterial triggers anomalous complement activation or high coagulation indices?
Every complex dataset is accompanied by a technical review session with our senior immunotoxicologists to evaluate surface charge effects, corona formation, and potential mitigation strategies for your formulation.
⭐⭐⭐⭐⭐
"We encountered unexpected complement activation spikes with our polymer-lipid nanoparticle candidates. Their toxicology team worked closely with us to isolate surface-charge interaction factors, helping us adjust our PEGylation density before our preclinical safety gate."
Nanomedicine Therapeutics Startup
August 24, 2026
⭐⭐⭐⭐⭐
"The thoroughness of their hemocompatibility reporting and raw data transparency made our regulatory filing preparation entirely seamless. Their team handled our difficult-to-disperse formulations with impressive technical precision."
Biopharmaceutical R&D Enterprise
July 12, 2026
⭐⭐⭐⭐⭐
"We needed urgent batch-to-batch hemocompatibility screening to meet an aggressive investor milestone. They delivered comprehensive kinetic profiles within an accelerated timeline without sacrificing any assay depth or data integrity."
Targeted Drug Delivery Developer
June 05, 2026
Do not know how to place an order, please refer to the flow chart shown below.
Submit quotation request |
A technical manager will contact you within 24 hours |
You will review and approve the final price and place an order |
Confirm with you and make the payment |
Instruct you to ship your samples and form |
Analytic report delivery |